Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Irene Golán"'
Autor:
Caroline Gélabert, Panagiotis Papoutsoglou, Irene Golán, Eric Ahlström, Adam Ameur, Carl-Henrik Heldin, Laia Caja, Aristidis Moustakas
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-26 (2023)
Abstract Background Long non-coding RNAs (lncRNAs) regulate cellular processes by interacting with RNAs or proteins. Transforming growth factor β (TGFβ) signaling via Smad proteins regulates gene networks that control diverse biological processes,
Externí odkaz:
https://doaj.org/article/a582c71957894d6caef289ea2cc1fa2b
Autor:
Pedro García‐Gómez, Irene Golán, Mahsa S. Dadras, Artur Mezheyeuski, Claudia Bellomo, Kalliopi Tzavlaki, Anita Morén, Jordi Carreras‐Puigvert, Laia Caja
Publikováno v:
Molecular Oncology, Vol 16, Iss 9, Pp 1891-1912 (2022)
Glioblastoma (GBM) is the most aggressive and common glioma subtype, with a median survival of 15 months after diagnosis. Current treatments have limited therapeutic efficacy; thus, more effective approaches are needed. The glioblastoma tumoural mass
Externí odkaz:
https://doaj.org/article/bcbbc3ef2f3e4c95b309c91559fbcb09
Autor:
Andrea Chisari, Irene Golán, Sabrina Campisano, Caroline Gélabert, Aristidis Moustakas, Patricia Sancho, Laia Caja
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Malignant cells are commonly characterised by being capable of invading tissue, growing self-sufficiently and uncontrollably, being insensitive to apoptosis induction and controlling their environment, for example inducing angiogenesis. Amongst them,
Externí odkaz:
https://doaj.org/article/3cf403a8496b477b991635169e8bfb38
Autor:
Rodríguez de la Fuente, Laura, Cancela, Irene Golán, Estévez-Salguero, Ánxela M., Iglesias, Pablo, Costoya, José A.
Publikováno v:
In Analytica Chimica Acta 15 August 2022 1221
Autor:
Costoya, Pablo Iglesias, Marcos Seoane, Irene Golán-Cancela, Máximo Fraga, Victor M. Arce, Jose A.
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 10; Pages: 8849
In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhib
Autor:
Pablo Iglesias, Marcos Seoane, Irene Golán-Cancela, Maximo Fraga, Víctor M. Arce, Jose A. Costoya
In recent years, new therapies have been developed based on molecules that target mo-lecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly (ADP-ribose) polymerase 1 (PARP1) inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d0a416b32fcf6ca6a7a03be7fa84b37
https://doi.org/10.20944/preprints202304.0530.v1
https://doi.org/10.20944/preprints202304.0530.v1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pablo Iglesias, Marcos Seoane, Irene Golán-Cancela, Máximo Fraga, Victor M. Arce, Jose A. Costoya
Publikováno v:
International Journal of Molecular Sciences. 24:8849
In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhib
Autor:
Laura Rodríguez de la Fuente, Irene Golán Cancela, Ánxela M. Estévez-Salguero, Pablo Iglesias, José A. Costoya
Publikováno v:
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
instname
The development of new diagnostic tools in tumor pathology allows the optimization of individualized therapies in cancer patients. The functional optical image provides a unique opportunity to identify the pathophysiological characteristics of each t
Autor:
Irene Golán-Cancela, Jose A. Costoya, Pablo Iglesias, Marcos Seoane, Máximo Fraga, Víctor M. Arce, Isabel Castro-Piedras
In recent years, poly (ADP-ribose) polymerase (PARP) inhibitors have heen evaluated for treating homologous recombination-deficient tumors, taking advantage of synthetic lethality. However, increasing evidence indicates that PARP proteins exert sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9880a854a69665b35f8686d9bbe3b4